Duopharma eyes 10% revenue growth

The higher target for 2024 would be driven by both public and export portfolios.

KUALA LUMPUR: Duopharma Biotech Bhd aims for a 10% revenue growth this year, up from RM704.73mil achieved in the financial year ended Dec 31, 2023.

Group managing director Leonard Ariff Abdul Shatar said the higher target for 2024 would be driven by both public and export portfolios.

“The current contribution from the public portfolio stands at 48%, with 25% of that contributed by the approved products purchase list tenders secured from the Health Ministry.

“Recent contracts secured from Pharmaniaga Sdn Bhd, worth RM578.09mil, contribute 10% of the portfolio,” he told reporters after the company’s AGM yesterday. — Bernama